BXP.LSE

Beximco Pharmaceuticals Limited

BXP.LSE, UK

Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals PLC. was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

https://www.beximcopharma.com

Stock Price

GBp 0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
BXP.LSE
stock
BXP.LSE

Xp Power Share Price (XPP) London South East

Read more →

Finn Analysis

(Last Updated 2024-12-31)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

4.72

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.38

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

3.68 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.48 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-2.28 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.41

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Beximco Pharmaceuticals Limited

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-12-31

EPS Actual

2.6754

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2024-12-31)

Deep Value
Strong Deep Value(9.5)
Defensive
Highly Defensive(8)
Dividend
Weak Dividend Profile(2)
Economic Moat
Wide Moat Company(6.3)
GARP
Fair GARP(5.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(4.5)
Net Net
Strong Net-Net(6.5)
Quality
Moderate Quality(5.5)
Value
Undervalued(8)

Income Statement

(Last Updated 2024-12-31)

Revenue

£ 0

Cost Of Revenue

£ 0

Gross Profit

£ 0

Operating Expenses

£ 0

Operating Income

£ 0

Interest Expense

£ 0

Pretax Income

£ 0

Net Income

£ 0

Income Tax Expense

£ 0

EBITDA

£ 0

Total Other Income Expense Net

£ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-12-31)

Cash

£ 0

Short Term Investments

£ 0

Receivables

£ 0

Inventories

£ 0

Total Current Assets

£ 0

Property Plant Equipment

£ 0

Total Assets

£ 0

Payables

£ 0

Short Term Debt

£ 0

Long Term Debt

£ 0

Total Liabilities

£ 0

Equity

£ 0

Trend

Cash Flow

(Last Updated 2024-12-31)

Net Income

£ 0

Depreciation

£ 0

Change In Working Capital

£ 0

Cash From Operations

£ 0

Capital Expenditures

£ 0

Cash From Investing

£ 0

Cash From Financing

£ 0

Net Change In Cash

£ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.